menu
    • menu

    Company profile for CymaBay Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC). The PBC program is currently on hold. Our pipel...
    We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC). The PBC program is currently on hold. Our pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CymaBay TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    7575 Gateway Blvd., Suite 110 Newark, CA 94560
    Telephone
    Telephone
    +1 (510) 293-8800
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.cymabay.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    DCAT Week

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Gilead liver disease med still delivers ahead of FDA verdict
    Gilead liver disease med still delivers ahead of FDA verdict

    20 May 2024

    // James Waldron FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/gileads-recently-acquired-liver-disease-med-continues-deliver-goods-ahead-fda-verdict

    James Waldron FIERCE BIOTECH
    20 May 2024
    Share Share
    Gilead Announces Expiration of Waiting Period for CymaBay Tender Offer
    Gilead Announces Expiration of Waiting Period for CymaBay Tender Offer

    11 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240311327601/en

    BUSINESSWIRE
    11 Mar 2024
    Share Share
    CymaBay Announces EMA Accepts for Review the MAA for Seladelpar
    CymaBay Announces EMA Accepts for Review the MAA for Seladelpar

    04 Mar 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/03/04/2839523/37067/en/CymaBay-Announces-European-Medicines-Agency-Accepts-for-Review-the-Marketing-Authorization-Application-for-Seladelpar-for-the-Treatment-of-Primary-Biliary-Cholangitis.html

    GLOBENEWSWIRE
    04 Mar 2024
    Share Share
    CymaBay Reports Fourth Quarter & Year Ended December 31, 2023 Financial Results
    CymaBay Reports Fourth Quarter & Year Ended December 31, 2023 Financial Results

    28 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/28/2837495/37067/en/CymaBay-Reports-Fourth-Quarter-and-Year-Ended-December-31-2023-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    28 Feb 2024
    Share Share
    CymaBay board pushed for 50 cent top up to Gilead's $32.50 offer
    CymaBay board pushed for 50 cent top up to Gilead's $32.50 offer

    26 Feb 2024

    // Annalee Armstrong FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/cymabay-board-pushed-50-cent-top-gileads-3250-share-offer

    Annalee Armstrong FIERCE BIOTECH
    26 Feb 2024
    Share Share
    The New England Journal Publishes Positive Phase 3 of CymaBay's Seladelpar
    The New England Journal Publishes Positive Phase 3 of CymaBay's Seladelpar

    21 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/the-new-england-journal-of-medicine-publishes-positive-phase-3-response-data-of-cymabays-seladelpar-in-primary-biliary-cholangitis-302068089.html

    PR NEWSWIRE
    21 Feb 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search